Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (263)	11/16/1999 4:20:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 427

Biowa, It's not that surprising they went into the 20's if you read their nice calm release from yesterday: Colorado Pharmaceutical Co. Makes Cancer Drug History; MEDIA ADVISORY: PRESS CONFERENCE 11/17 Ribozyme Pharmaceuticals, Inc. (RPI), the Boulder CO pharmaceutical and biotech company, will disclose important corporate and product news concerning its unique cancer drug, Angiozyme(TM): <snip> Angiozyme -- it's cancer drug -- has made significant progress. Angiozyme is now in human clinical trials at the Cleveland Clinic Foundation and has taken an important step forward ... making both clinical history and industry news. RPI CEO & President, Ralph E. Christoffersen, Ph.D., and other senior RPI staff, will explain Angiozyme and its recent history-making leap, an achievement which may be of great significance to cancer patients everywhere. "Cancer drug history" and "history-making leap" for a drug that seems to have never been tried on cancer patients? (I'm not real certain on this, but it looked to me that the Phase I was in healthy volunteers, and they are only now starting on a Phase II). Peter